QTX3034   Click here for help

GtoPdb Ligand ID: 14671

Synonyms: Compound 64 [WO2023154766] | QTX-3034
Compound class: Synthetic organic
Comment: QTX3034 is an allosteric KRAS inhibitor. It is one of the compounds claimed in Quanta Therapeutics' patent WO2023154766A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 79.58
Molecular weight 663.23
XLogP 3.16
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(C)C(=O)C1=NN2CCCN(CC2=C1Cl)C3=C4CN(C)[C@@]5(CCCC6=C5C=CC=C6)CC4=NC(=N3)OC[C@]78CCCN8C[C@@H](C7)F
Isomeric SMILES C1[C@@H](F)CN2CCC[C@@]12COC=3N=C(N4CCCN5N=C(C(=O)N(C)C)C(Cl)=C5C4)C=6CN(C)[C@]7(C=8C=CC=CC8CCC7)CC6N3
InChI InChI=1S/C35H44ClFN8O2/c1-41(2)32(46)30-29(36)28-21-43(14-8-16-45(28)40-30)31-25-20-42(3)35(13-6-10-23-9-4-5-11-26(23)35)18-27(25)38-33(39-31)47-22-34-12-7-15-44(34)19-24(37)17-34/h4-5,9,11,24H,6-8,10,12-22H2,1-3H3/t24-,34+,35+/m1/s1
InChI Key VHGONFNSHQOROQ-WOGOVJIYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
QTX3034 was progressed as a clinical candidate for tumours with the oncogenic KRASG12D mutation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06227377 QTX3034 in Patients With KRAS G12D Mutation Phase 1 Interventional Quanta Therapeutics